Rituximab (Mabthera)

A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

Also Known As:

Networked: 15450 relevant articles (3055 outcomes, 2704 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Salles, Gilles: 92 articles (08/2022 - 01/2002)
2.	Coiffier, Bertrand: 64 articles (01/2019 - 01/2002)
3.	Friedberg, Jonathan W: 63 articles (12/2022 - 06/2002)
4.	Sehn, Laurie H: 61 articles (01/2022 - 08/2005)
5.	Czuczman, Myron S: 56 articles (01/2018 - 02/2002)
6.	Morschhauser, Franck: 54 articles (03/2022 - 01/2003)
7.	Tobinai, Kensei: 53 articles (03/2021 - 01/2002)
8.	Cheson, Bruce D: 52 articles (01/2020 - 01/2002)
9.	Cartron, Guillaume: 51 articles (03/2022 - 02/2002)
10.	Gascoyne, Randy D: 51 articles (01/2021 - 08/2005)

Related Diseases

1.	Lymphoma (Lymphomas) 10/03/2022 - "Indeed, incorporation of rituximab into the regimen for indolent non-Hodgkin's lymphomas (NHLs) has dramatically improved treatment response and disease outcome. " 01/01/2015 - "Additionally, prophylaxis was dramatically effective in preventing PCP in rituximab-received lymphoma patients, suggesting that rituximab should be recommended for these patients. " 01/01/2015 - "Rituximab as a single agent is highly effective and tolerable in first-line treatment of primary MALT Ocular adnexal Lymphomas. " 07/01/2010 - "In conclusion, immunochemotherapy treatment dramatically improved the outcome of patients with nodal DLBCL; however, its effect was less in primary extranodal cases, so the prognosis of patients with nodal and extranodal lymphomas has been equalized in the rituximab era." 10/01/2009 - "Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphomas (NHL), but the dosing regimen currently used should be optimized. "
2.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/01/2021 - "Survival rates of PTLD with diffuse large B-cell lymphoma (DLBCL) phenotype have improved due to the introduction of rituximab, however, reports on curative management of refractory PTLD are scarce. " 01/01/2019 - "Rituximab-based chemoimmunotherapy has resulted in a marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). " 01/01/2016 - "Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission." 08/01/2015 - "Despite the improvement in overall survival in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era, the occurrence of central nervous system (CNS) relapse heralds a very poor prognosis. " 08/01/2012 - "Since the introduction of rituximab (R), the prognosis for diffuse large B-cell lymphoma (DLBCL) has markedly improved. "
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/2017 - "Rituximab is widely used for the treatment of non-Hodgkin lymphoma, being a key component in most therapeutic regimens. " 10/01/2016 - "Pediatric relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) has been reported to be extremely difficult to cure, but rituximab is expected to be effective in improving the prognosis of pediatric R/R B-NHL patients. " 04/01/2012 - "AIMS Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphoma (NHL). " 04/01/2006 - "CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. " 04/01/2004 - "Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin's lymphoma (NHL). "
4.	Neoplasms (Cancer) 01/01/2018 - "While rituximab has dramatically improved outcomes for patients with CD20+ malignancies for two decades, responses are not universal and resistance can develop. " 01/01/2017 - "Although discovery of the anti-CD20 antibody rituximab has markedly improved outcomes in B-cell NHL, rituximab resistance remains an important obstacle to successful treatment of these tumors. " 04/08/2010 - "Optimal tumor eradication required CD20 targeting, with 87% of mice cured of rituximab-insensitive tumors. " 05/01/2004 - "Administering 4HPR and rituximab to mice with established tumors induced complete responses (CRs) in 80% of animals compared with 20% to 40% CRs using either agent alone (P =.07), resulting in significantly improved survival. " 05/01/2019 - "In the modeling, including treatment arm as a categorical covariate and tumor burden as a continuous time-varying covariate on overall rituximab clearance significantly improved fitting of the data. "
5.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/01/2016 - "Despite the improvement in prognosis since the advent of rituximab, follicular lymphoma is still incurable and remains the cause of death of most afflicted patients. " 01/01/2019 - "Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). " 11/01/2019 - "The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. " 03/01/2015 - "Rituximab was approved in France in 2004, following randomized trials that demonstrated efficacy in newly diagnosed high tumour burden follicular lymphoma (FL). " 01/01/2017 - "Randomised trials of rituximab maintenance (MR) for patients with follicular lymphoma support improved progression-free survival (PFS), but the effect on overall survival has been inconclusive. "

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	Monoclonal Antibodies
3.	Vincristine (Oncovin)
4.	Doxorubicin (Adriamycin)
5.	Prednisone (Sone)
6.	Bendamustine Hydrochloride
7.	Steroids
8.	fludarabine
9.	Adrenal Cortex Hormones (Corticosteroids)
10.	Methotrexate (Mexate)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Stem Cell Transplantation
4.	Radiotherapy
5.	Aftercare (After-Treatment)